BANK VONTOBEL/CALL/BIONTECH ADR/110/1/21.06.24 Share Price

Warrant

JX08V

DE000VM29M51

Market Closed - Euronext Paris 10:00:00 28/05/2024 pm IST
0.047 EUR -53.47% Intraday chart for BANK VONTOBEL/CALL/BIONTECH ADR/110/1/21.06.24
Current month-11.32%
1 month+14.63%
Date Price Change
28/24/28 0.047 -53.47%
27/24/27 0.101 +21.69%
24/24/24 0.083 -55.14%
23/24/23 0.185 +20.92%
22/24/22 0.153 +466.67%

Real-time Euronext Paris

Last update May 28, 2024 at 10:00 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer Vontobel Vontobel
JX08V
ISINDE000VM29M51
Date issued 03/10/2023
Strike 110 $
Maturity 21/06/2024 (24 Days)
Parity 1 : 1
Emission price 1.61
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.075
Lowest since issue 0.017
Delta0.02x
Omega 36.42
Premium17.92x
Gearing1826.85x
Moneyness 0.8485
Difference Strike 15.9 $
Difference Strike %+14.45%
Spread 0.01
Spread %19.23%
Theoretical value 0.0470
Implied Volatility 29.93 %
Total Loss Probability 98.35 %
Intrinsic value 0.000000
Present value 0.0470
Break even 110.05 €
Theta-0.05x
Vega0.01x
Rho0x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
86.52 EUR
Average target price
104.7 EUR
Spread / Average Target
+21.01%
Consensus
  1. Stock Market
  2. Warrants
  3. JX08V Warrant